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Abstract
Plasmid-acquired carbapenemases in Enterobacteriaceae, which were ﬁrst discovered in Europe in the 1990s, are now increasingly being
identiﬁed at an alarming rate. Although their hydrolysis spectrum may vary, they hydrolyse most b-lactams, including carbapenems. They
are mostly of the KPC, VIM, NDM and OXA-48 types. Their prevalence in Europe as reported in 2011 varies signiﬁcantly from high
(Greece and Italy) to low (Nordic countries). The types of carbapenemase vary among countries, partially depending on the cultural/
population exchange relationship between the European countries and the possible reservoirs of each carbapenemase. Carbapenemase
producers are mainly identiﬁed among Klebsiella pneumoniae and Escherichia coli, and still mostly in hospital settings and rarely in the
community. Although important nosocomial outbreaks with carbapenemase-producing Enterobacteriaceae have been extensively
reported, many new cases are still related to importation from a foreign country. Rapid identiﬁcation of colonized or infected patients
and screening of carriers is possible, and will probably be effective for prevention of a scenario of endemicity, as now reported for
extended-spectrum b-lactamase (mainly CTX-M) producers in all European countries.
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Introduction
Carbapenemases are enzymes that are able to hydrolyse
nearly all b-lactam antibiotics, including carbapenems. They
are classiﬁed into different molecular classes (A, B and D),
and have become epidemiologically important in different
parts of the world, including Europe, in recent years [1–4].
Most carbapenemases are plasmid-mediated, and have been
mainly reported in Enterobacteriaceae, Pseudomonas aerugin-
osa, and Acinetobacter baumannii (Table 1).
In 2005, Walsh et al. [5] published a review article entitled
‘Metallo-b-lactamases: the quiet before the storm?’ Although
they speciﬁcally reviewed the biochemical and genetic charac-
terization of metallo-b-lactamases (MBLs), they also pointed
out that the continued spread of carbapenemases worldwide
would result in a clinical catastrophe and could cause a future
public health crisis. Unfortunately, the current epidemiological
situation in Europe conﬁrms this prediction at a level that is
even worse than expected. At the time of that review, most
of the carbapenemases were conﬁned to P. aeruginosa, only
anecdotal reports of currently important carbapenemases
such as KPCs belonging to class A [6] or OXA-48 belonging
to class D [7] had been published, and NDM-1 belonging to
class B had not been described [8].
In this review, we describe the evolving situation of
carbapenemase-producing Enterobacteriaceae (CPE) in Eur-
ope, highlighting epidemiological data from representative
countries.
From Extended-spectrum b-Lactamases
(ESBLs) to Carbapenemases
The interest in b-lactam resistance in Enterobacteriaceae dur-
ing the 2000s was dominated by the increase in the number
of Enterobacteriaceae producing ESBLs, particularly the CTX-
M enzymes [9]. Characterization of the genetic environment
of the blaCTX-M genes and the respective plasmid carriers
revealed the existence of efﬁcient genetic machineries con-
tributing to the spread of these resistance determinants. In
addition, data obtained from epidemiological typing tools
such as multilocus sequence typing revealed the spread of
speciﬁc Escherichia coli and Klebsiella pneumoniae clones
expressing ESBL phenotypes, even in the community setting
[10–12]. Cumulative experience with ESBL producers sup-
ports the idea that, once the prevalence surpasses a critical
threshold, their eradication from bacterial communities is
nearly impossible.
At present, the interest in b-lactamases has turned to carba-
penemases, particularly in Enterobacteriaceae [1,3,4,13]. The
emergence of ESBLs and that of carbapenemases have had dif-
ferent epicentres, but lately they have spread to different parts
of the world. ESBLs appeared almost simultaneously in Europe
(Germany) and South America (Argentina), whereas carbapen-
emases appeared mainly in Asia (Japan and India) and North
America (USA) [4]. With ESBLs, it seems that, after quiet and
continuous spread, outbursts occurred in many parts of the
world, including Europe [14]. This could also have been the
TABLE 1. General classiﬁcation of carbapenemases and frequency of isolation
Molecular classa
(functional groupb) Enzymes
Inhibited by
ATM Organisms
Gene
location
Epidemiological
relevanceCLA EDTA
A (2f) Sme-1 to Sme-3, IMI-1 to IMI-3, NmcA,
SFC-1
± – R Serratia marcescens and Enterobacter cloacae Ch ±
KPC-2c to KPC-13 ± – R Enterobacteriaceae, Pseudomonas aeruginosa,
Acinetobacter baumannii
Pl ++++
GES-1 to GES-20 + – S/R Enterobacteriaceae, P. aeruginosa, A. baumannii Pl +
B (3) IMP-1 to IMP-33, VIM-1 to VIM-33, NDM-1
to NDM-6, SPM-1, SIM, GIM, IND-1 to
IND-7, AIM, DIM, KHM
– + S Enterobacteriaceae, P. aeruginosa, and other
GNNFB
Pl/Ch ±/+++
D (2df)d OXA-23 group (OXA-23, OXA-27,
OXA-49)
OXA-24 group (OXA-24, OXA-25,
OXA-26, OXA-40, OXA-72)
OXA-40 group (OXA-40, OXA-143)
OXA-58
OXA-48 group (OXA-48, OXA-54,
OXA-181)
± –e S A. baumannii, P. aeruginosa, Enterobacteriaceae Pl/Ch ++
ATM, aztreonam; Ch, chromosomal; CLA, clavulanate; GNNFB, gram-negative non fermentative bacilli; Pl, plasmid; R, resistant; S, susceptible.
aAmbler classiﬁcation.
bBush, Jacoby and Medeiros classiﬁcation.
cKPC-1 was later found to be identiﬁcal to KPC-2.
dOnly class D carbapenemases representative of different groups have been included.
eSome OXA enzymes may be slightly inhibited by EDTA.
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case with carbapenemases. Within the Enterobacteriaceae fam-
ily, class A carbapenemases (KPC enzymes) emerged in North
Carolina (USA) in 1996 and later spread to Europe; class B
emerged as VIM-1 in E. coli in Greece, but rapidly spread in
K. pneumoniae, becoming endemic in that country as well as in
other European countries; and OXA-48 belonging to class D
emerged in Turkey in K. pneumoniae, and later spread to other
Mediterranean countries [4,15,16].
Currently, carbapenemases in Enterobacteriaceae are mainly
found in K. pneumoniae, and to a much lesser extent in E. coli
and other enterobacterial species, with a higher prevalence
in southern Europe and Asia than in other parts of the
world. It has recently been suggested that the future global
spread of CPE will be dominated in the hospital setting by
K. pneumoniae expressing all types of carbapenemase, mainly
KPC, VIM, NDM, and OXA-48, and in the community by
E. coli expressing NDM or OXA-type (OXA-48 and OXA-
181) enzymes [4]. Moreover, as these enzymes are able to
hydrolyse nearly all b-lactam antibiotics, and CPE isolates are
normally resistant to non-b-lactam antibiotics, selection pres-
sure is high, increasing the probability of persistence [17],
even though efﬁcient clones (high-risk clones) express these
carbapenemases, increasing the likelihood of spread and
endemicity [18].
Carbapenemases in Europe: a north–south
distribution?
In a summary from a meeting on carbapenem-non-suscepti-
ble Enterobacteriaceae published in 2010 [16], European
countries were classiﬁed into a numerical staging system
according to the epidemiological situation. This scale
includes: 0, no cases reported; 1, sporadic occurrence; 2a,
single-hospital outbreaks; 2b, sporadic hospital outbreaks; 3,
regional outbreaks; 4, interregional spread; and 5, endemic
situation. At the time of that summary, July 2010, two coun-
tries each were graded 5 (Greece and Israel) and 4 (Italy and
Poland), three were graded 3 (France, Germany, and Hun-
gary), three were graded 2a (Belgium, Spain, and England/
Wales), and ﬁve were graded 2b (Cyprus, The Netherlands,
Norway, Scotland, and Sweden). Other European countries
were graded 1 or 0. The situation changed during 2011, as
the number of reports from different European countries
increased dramatically. Fig. 1 shows the current situation in
different European countries according to this epidemiologi-
cal scale, and carbapenemase types in different countries or
geographical areas.
According to the EARS-Net surveillance study (http://
ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/
Pages/database.aspx), antimicrobial resistance in northern
European countries is lower than in southern European
countries. This is true for ESBL-producing organisms as
well as for methicillin-resistant Staphylococcus aureus, but
only partially true for carbapenemase-producing E. coli and
K. pneumoniae (Fig. 2). These ﬁgures indicate that different
factors might be inﬂuencing the emergence and spread of
carbapenemases than that of ESBLs and/or methicillin-
resistant S. aureus. Antimicrobial use and different policies
and/or implementation of infection control measures can
be only partly responsible for these differences. Importation
of carbapenemases from speciﬁc areas in Europe as a
Endemic
Interregional spread
Regional spread
Independent hospital outbreaks
Single-hospital outbreaks
Sporadic occurrence
Not reported / no data 
KPC
VIM
NDM 
OXA-48
Other countries: 
Israel
Luxembourg
FIG. 1. European situation regarding carbapenemase-producing Enterobacteriaceae, using an epidemiological scale of nationwide expansion (data
have been updated from reference 17) and carbapenemase types in different countries or geographical areas known until January 2012.
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consequence of cross-border transfer of patients, travel,
medical tourism and refugees might play also an important
role in this outburst [15,19,20]. This has been clearly dem-
onstrated for carbapenemases of different molecular clas-
ses, including KPC [21,22], NDM-1 [23], and OXA-48
[24–26].
Emergence and Spread of CPE in Different
European Countries
Most CPE data for Europe have come from microbiological
studies carried out during the emergence of these isolates in
speciﬁc countries or when describing outbreaks. These data
are not always in agreement with local and supranational sur-
veillance reports. For these studies, clinical breakpoints are
used, and they do not introduce concepts to discriminate
non-wild-type populations from those with high-level or
low-level resistance mechanisms. This can be the case for
enterobacterial isolates with low-level expression of
carbapenemases [27,28].
Implementation of national guidelines for reporting multi-
drug-resistant (MDR) organisms may inﬂuence communica-
tion and publishing on the emergence of CPE. Some
European countries have frequently reported the emergence
of these isolates, whereas in others no epidemiological
information is available. Nevertheless, in these countries
information has became available when patients have been
transferred to the former countries. This has been, for
instance, the case for the detection of NDM-1 in the Balkans
[15]. Moreover, countries with very active investigators have
a large number of reports, despite their countries having a
lower prevalence than others. This is, for instance, the case
for France and UK as compared with other countries. The
current information on CPE in Europe is presented below.
Greece
According to the data of the EARS-Net, Greece is the Euro-
pean country with the highest incidence of CPE isolates, and
has been considered to be the epicentre of the spread of
VIM-producing Enterobacteriaceae, mainly K. pneumoniae, to
other EU countries [29,30]. Recent reports of the EARS-Net
database (http://ecdc.europa.eu/en/activities/surveillance/
EARS-Net/database/Pages/database.aspx) show that up to
49% of K. pneumoniae invasive isolates in Greece exhibit
resistance to carbapenems, but this percentage can be even
higher in intensive-care units (ICUs) [31].
In November 2001, an E. coli strain exhibiting decreased
susceptibility to carbapenems was isolated from a hospital-
ized patient [32]. This strain was the ﬁrst CPE isolate
obtained in Europe. The strain carried a self-transferable
plasmid coding for VIM-1. The blaVIM-1 gene, along with the
aacA7, dhfrI and aadA genes, was included as a gene cassette
in a class 1 integron (In-e541). Soon, VIM-1-producing E. coli
strains were isolated in Crete [33] with blaVIM-1 genes
located in a class 1 integron that was different from the ini-
tially characterized one. In 2002, distinct VIM-1-producing
K. pneumoniae strains exhibiting various carbapenem resis-
tance levels were recovered from ICU patients in three ter-
tiary-care institutions in Athens [34]. Since then, polyclonal
outbreaks of VIM-positive K. pneumoniae isolates have been
described in hospitals throughout the country [31,35]. The
majority of the VIM producers harboured variants of a self-
transmissible plasmid of the IncN family that contained In-
e541[36]. Nevertheless, the blaVIM-1 gene was increasingly
found in other replicons as well as chromosomes of entero-
bacterial species other than K. pneumoniae and E. coli. Also,
reshufﬂing of the blaVIM gene cassette in various class 1 integ-
rons and the emergence of novel blaVIM variants have
occurred over time [37–39].
KPC-2-producing K. pneumoniae was ﬁrst reported in
Greece in 2008 [40], although the introduction of KPC-2-
producing K. pneumoniae in this country started 1 year
before, as the ﬁrst outbreak occurred in Crete in 2007 [41].
Since then, the continuous spread of these isolates, later
demonstrated to belong to the sequence type (ST)258 line-
age [42], has led to a nationwide epidemic. The blaKPC-2 gene
is commonly carried by plasmids of similar size (c. 100 kb)
belonging to the FIIk incompatibility group and associated
mainly with the Tn4401a isoform, whereas the Tn4401b iso-
form has been sporadically detected.
Today, ST258 is still predominant among KPC-positive
K. pneumoniae isolates, but additional KPC-producing clones
(ST147, ST383, ST133, ST274, and ST323, among others)
FIG. 2. Rates of non-susceptibility (intermediate plus resistant) of
Klebsiella pneumoniae to carbapenems in European countries. Data
were obtained from the EARS-Net database (2010). (http://ecdc.euro
pa.eu/en/activities/surveillance/EARS-Net/database/Pages/database.as
px). Only those countries with non-susceptible isolates are included.
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have emerged. It is of note that ongoing monitoring of carba-
penem-non-susceptible K. pneumoniae has revealed the emer-
gence of clones expressing both VIM and KPC enzymes, but
at present their frequency of isolation is low. Also, resistance
to colistin has already emerged, and pan-drug resistant iso-
lates are being increasingly reported [43–45]. Finally, out-
breaks caused by E. coli strains producing KPC-2 in long-
term-care facilities have recently been reported [46]. These
ﬁndings show the potential of the KPC-positive Enterobacteri-
aceae isolates to spread outside the hospital environment
and to circulate in the community, as has occurred with VIM
producers in Spain [47] (R. Canto´n and P. Ruiz-Garbajosa,
unpublished data). Unlike in other European countries, KPC-
3, NDM and OXA-48 producers have not yet been reported
in Greece.
Turkey
Resistance in Turkey is not currently recorded in the EARS-
Net database. Nevertheless, in the last available data from
this surveillance study before transition to the ECDC (for-
merly the EARSS) and corresponding to 2008, carbapenem
resistance in K. pneumoniae was 3%, similar to that in Italy
and the Balkan countries (http://ecdc.europa.eu/en/activities/
surveillance/EARS-Net/database/Pages/database.aspx). This
situation, as that in other European countries, might have
changed in the last few years with the increasing prevalence
of CPE.
The most important carbapenemase in Turkey is OXA-48.
First detected in 2001 in Istanbul in K. pneumoniae [7], it is
now well disseminated in the Mediterranean and western
European countries [4]. This class D carbapenemase has
been found in different Enterobacteriaceae, such as Citrobacter
freundii [48], Providencia rettgeri, and Enterobacter cloacae [49],
and even in E. coli [50,51]. Although the majority of these
descriptions were associated with single cases, important
outbreaks have also been described [52]. In addition,
OXA-48 has been found in patients transferred from Turkey
to other European countries [24]. Further analysis of the
OXA-48-producing isolates demonstrated that this enzyme
was not exclusively linked with a single clone, and that the
blaOXA-48 gene was associated with either transposon
Tn1999 or transposon Tn1999.2 within transferable non-
typeable plasmids of 70 or 150 kb [53]. Despite these obser-
vations, recent data on OXA-48-producing K. pneumoniae
isolates in western European countries showed the dissemi-
nation of a single clone that is also found in Morocco [53].
OXA-48 producers might be also circulating in the commu-
nity in Turkey (P. Nordmann, unpublished data).
MBLs in Enterobacteriaceae were reported in Turkey in
2003, and correspond to a VIM-5-producing K. pneumoniae
isolate (Midilli et al., KLIMIK Congress, Istanbul, Turkey,
Abstract, 2003, S-21). This ﬁve amino acid substitution
variant of VIM-1 might have spread rapidly, as it was also
found in Enterobacter cloacae [54] and in P. aeruginosa [55]
during this period. Moreover, it might have coexisted with
the VIM-1 that was later reported in P. aeruginosa [56] and in
K. pneumoniae [57]. Remarkably, VIM-1-producing and
SHV-12-producing K. pneumoniae isolates were identiﬁed in
Norway in a patient with a recent history of hospitalization
in Turkey [58]. Other MBL detected in Enterobacteriaceae
was IMP-1 in K. pneumoniae in 2003 [59] and in Enterobacter
cloacae in 2003 and in 2004 [60]. NDM enzymes have not
yet been reported in Turkey.
Israel
Before 2006, carbapenemases were rarely identiﬁed in Israel.
They included a single case of VIM-producing P. aeruginosa in
2001 (Y. Carmeli, unpublished data), and a few cases of
KPC-2 in Enterobacter spp. and E. coli [61,62]. Importation of
KPC producers from the USA could not be demonstrated.
In a large survey in all major Israeli hospitals conducted
between 2004 and 2005, 1011 E. coli and Klebsiella isolates
were tested, and none of them contained a carbapenamase
[63,64]. In early 2006, small polyclonal outbreaks of KPC-2-
producing K. pneumoniae occurred in Israeli hospitals, shortly
followed by a multicentre outbreak caused primarily by a sin-
gle KPC-3 clone termed clone Q as assessed by pulsed-ﬁeld
gel electrophoresis [65,66]. The epidemic clone Q was later
shown to have a similar pattern to that of isolates implicated
in large US outbreaks since the early 2000s [67], and has
been shown to belong to the pandemic clone ST258, sug-
gesting importation from the USA [68]. The nationwide nat-
ure of this outbreak was identiﬁed only in early 2007, and a
national intervention to limit the spread of KPC-producing
Enterobacteriaceae was initiated only after 1275 cases had
already occurred in 27 acute-care hospitals (175 cases per
million population). At the peak of the outbreak, 186 new
cases were identiﬁed monthly. Indeed, the EARSS reports
documented a rise of carbapenem resistance in Klebsiella iso-
lates causing bacteraemia from 0% to 22% between 2005 and
2008. Following the intervention, the incidence of clinical
cases of carbapenem-resistant Enterobacteriaceae in acute-
care hospitals stabilized at 40 cases per month by mid-2008
(5.3 cases per million population per month). The outbreak
and the national intervention are described in detail else-
where [69]. In parallel, it was observed that a large reservoir
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of carbapenem-resistant Enterobacteriaceae carriers was cre-
ated in long-term-care facilities [70]. Currently, carbapenem-
resistant Enterobacteriaceae rarely spread in the community.
In almost all Israeli acute-care hospitals, the risk of acquiring
CPE during a hospital stay is minimal (c. 1/1000 admissions);
however, the endemicity is maintained by the large reservoir
created in the long-term-care setting. KPC enzymes have not
been detected in Gram-negative non-fermenters in Israel.
Apart from KPC, a few cases of OXA-48 and NDM-1
have been introduced into Israel by tourism [71], and single
cases have been detected with no apparent foreign travel
relationship.
Italy, Croatia, and Slovenia
Italy was the ﬁrst European country to report acquired car-
bapenemases in Gram-negatives during the late 1990s. These
early reports included IMP-2 from A. baumannii [72,73] and
VIM-1 from P. aeruginosa [74] and Achromobacter xylosoxidans
isolates [75], and represented the ﬁrst descriptions of these
enzymes. Recently, the blaVIM-1 determinant has been
detected in a stored strain of Pseudomonas mosselii isolated in
Italy in 1994 [76], suggesting that the inﬂux of this carbape-
nemase gene in the clinical setting dates back to least the
early 1990s.
The ﬁrst report of CPE from Italy dates back to the early
2000s, with sporadic isolates of K. pneumoniae and Enterob-
acter cloacae producing VIM-4 [77]. Since then, several
reports have documented the presence of various Enterobac-
teriaceae (mostly K. pneumoniae, Enterobacter, and E. coli) pro-
ducing VIM-1-like enzymes [78–85]. However, such VIM-
producing Enterobacteriaceae have not undergone wide dis-
semination, unlike that observed in Greece during the same
period, and their spread remains low overall and mostly lim-
ited to sporadic cases or small clonal outbreaks, as was doc-
umented by a recent nationwide survey (G. M. Rossolini,
unpublished data). Nevertheless, VIM enzymes have been
associated with E. coli that are also associated with dissemi-
nation of ESBLs, such as ST131 [86].
A different evolution has been observed with K. pneumo-
niae producing KPC-type enzymes. Reported for the ﬁrst
time in late 2008, where the likely source was a medical
trainee from Israel [87], KPC-producing K. pneumoniae has
since undergone rapid and extensive dissemination in this
country, with several reports of hospital outbreaks [88–95].
The abrupt and remarkable increase in carbapenem resis-
tance rates in K. pneumoniae recently reported by the EARS-
Net surveillance system for Italy (from 1% to 2% during the
period 2006–2009 to 15% in 2010) (http://ecdc.europa.eu/en/
activities/surveillance/EARS-Net/database/Pages/database.aspx)
appears to be mostly related to the countrywide dissemina-
tion of KPC-producing K. pneumoniae, as shown by results
from a recent countrywide survey (G. M. Rossolini, unpub-
lished data). As in Greece, multifocal emergence of colistin-
resistant isolates of KPC-producing K. pneumoniae has been
observed [92] (Giani et al., 51st ICAAC, 2011, Abstract
C2669b), which is a matter of major concern, as colistin is
among the few drugs that retain activity against these organ-
isms, and is a cornerstone of antimicrobial chemotherapy for
infections caused by these organisms.
Most recently, isolates of E. coli and K. pneumoniae pro-
ducing NDM-1 [96,97] and OXA-48 [98], of likely cross-bor-
der origin, have also been reported in Italy, but the
dissemination of these carbapenemases appears to be still
very limited.
Few data are available on the dissemination of acquired
carbapenemases in countries bordering the eastern coast of
the Adriatic Sea. Most of them are associated with P. aerugin-
osa and Acinetobacter [99–102], but a case of OXA-48-pro-
ducing K. pneumoniae imported from Libya has recently been
found in Slovenia [103]. It is of note that dissemination of
NDM-1 is highly suspected in this area, as there are different
reports of the isolation of NDM-1-producing Enterobacteria-
ceae in patients from Balkan countries but admitted to other
European countries [15,104].
Spain and Portugal
As in other Mediterranean countries (Greece, Italy, and
France), the ﬁrst description of CPE in Spain concerned the
VIM type, and was published in 2005 [105]. In this study, an
E. coli isolate from a urinary tract infection and a K. pneumo-
niae isolate, recovered in 2003 during a surveillance study of
faecal ESBL carriers in Barcelona, were shown to produce
VIM-1. Since then, continuous penetration of different carba-
penemases from different molecular classes has been
observed, and both sporadic cases and important outbreaks
have been described [106–110].
The ﬁrst outbreak involving VIM-1 occurred at Ramo´n y
Cajal University Hospital (Madrid) in 2005 and 2006 [106].
Twenty-ﬁve patients (52% from the ICU) were infected and/
or colonized with single or multiple MBL-producing Entero-
bacteriaceae isolates, including K. pneumoniae, E. cloacae,
E. coli, and Klebsiella oxytoca). Clonal analysis revealed a com-
plex population structure, as all K. pneumoniae isolates
belonged to the same clone but different patterns were
found among the Enterobacter cloacae isolates. This complexity
was even higher when the genes and plasmids surrounding
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the blaVIM-1 gene were characterized. The blaVIM-1 gene was
detected within a 4.0-kb class 1 integron (In113, blaVIM-1–
aacA4–dfrII–aadA1–catB2) in K. pneumoniae and E. coli, and
within a 2.5-kb class 1 integron (In110, blaVIM-1–aacA4–
aadA1) in E. cloacae and K. oxytoca isolates. A 60-kb plasmid
belonging to the IncI1 group was detected in the epidemic
VIM-1-producing K. pneumoniae clone, whereas plasmids of
300 or 435 kb belonging to the IncH12 group were found
among E. cloacae isolates. Interestingly, the K. pneumoniae
and E. coli isolates also produce the ESBL SHV-12. Moreover,
class 1 integrons were associated with defective Tn402 vari-
ants also found in VIM-1-producing P. aeruginosa isolates
from the same institution, indicating potential interspecies
spread of different genetic determinants [111].
In 2009, the Spanish Network Research of Infectious Dis-
ease (REIPI) performed a surveillance study involving 35 hos-
pitals, with the aim of investigating the epidemiology of CPE
isolates in Spain (Miro´ et al., XIV Congress of the Spanish
Society of Infectious Diseaeses and Clinical Microbiology,
2010, Abstract 706). Only class B carbapenemase producers
were found (VIM-1 and IMP-22) in speciﬁc areas (Madrid,
Catalonia, Andalusia, and Balearic Islands), with a local prev-
alence of <0.2% of tested isolates. This situation might have
changed, as several descriptions of outbreaks caused by VIM
producers have been published since then, as well as spo-
radic cases affecting non-hospitalized patients [47,110–115].
One of these outbreaks was associated with the ST15 clone
previously associated with the spread of CTX-M-15 in cen-
tral Europe [110]. In addition, KPC-3 in K. pneumoniae
[107], but not belonging to ST258, and KPC-2 in C. freundii
[108], and NDM-1 in E. coli and K. pneumoniae [26,109,116]
have also emerged. Very recently, an outbreak caused by a
porin-deﬁcient K. pneumoniae isolate co-producing OXA-48
and CTX-M-15 was recognized [26]. The index case was a
patient transferred from an ICU in a hospital in Marrakech
(Morocco) to Barcelona. Sequence typing study revealed
that the OXA-48-producing, CTX-M-15-producing K. pneu-
moniae isolate belonged to the ST101 clone that was previ-
ously found in North African countries and that was
responsible from the spread of this enzyme in other Euro-
pean countries [117]. All of these descriptions conﬁrmed
the dissemination of carbapenemase-producing isolates in
Spain, which can even be found in hospital sewage water
[118].
In Portugal, with the exception of one report of a VIM-2-
producing K. oxytoca isolate, reports of VIM enzymes are
restricted to P. aeruginosa [119]. KPC enzymes have not
been described in clinical Enterobacteriaceae isolates, but a
KPC-producing E. coli isolate was very recently found in the
aquatic environment [120].
France and Switzerland
The ﬁrst description of CPE in France was in 1993, i.e.
NmcA in E. cloacae [121], the ﬁrst carbapenemase to be
identiﬁed in Enterobacteriaceae. Then, a VIM-1-producing
K. pneumoniae isolate also co-producing SHV-5 was reported
in 2004 and subsequently in a nosocomial outbreak [29,122].
The blaVIM-1 gene was part of a class 1 integron that also
included the aac6, dhfrI and aadA genes, and was similar to
those reported from strains isolated in Greece. The index
case was a patient transferred from Greece and identiﬁed on
admission as a CPE faecal carrier. This isolate spread to
other patients, but was not longer isolated after implementa-
tion of infection control barrier precautions. Also, VIM-19
with extended carbapenemase activity was isolated from
E. coli and K. pneumoniae from a patient transferred from
Algeria [123]. VIM-1-producing isolates have rarely been
reported, and have always been associated with patients
transferred from Greece, whereas IMP-producing Enterobac-
teriaceae have only been isolated once in France. However, a
study performed in 2010 showed penetration of VIM-1 and
IMP-1 [124]. This study addressed the prevalence of MDR
Gram-negative bacilli and ESBL-producing isolates in stool
specimens obtained from patients hospitalized for acute diar-
rhoea in a university hospital during a non-outbreak situa-
tion. Surprisingly, it revealed a high prevalence of CPE faecal
carriers (2.6% of patients). All isolates were E. cloacae with
VIM-1 or IMP-1.
The ﬁrst identiﬁcation of NDM-1 in France was in April
2009. It corresponded to an imported E. coli isolate from
India [125]. Subsequently, most NDM-1 cases were of Indian
origin, but there were also cases from Iraq and Serbia
[126,127]. In addition, in 2011, the ﬁrst reported case of
community-acquired NDM-1 producing CPE was identiﬁed in
the southern part of France [128], and this was followed by
another possible case of autochthonous acquisition [129].
NDM-1 has been found in K. pneumoniae by the use of real-
time PCR directly in clinical samples [130,131], and with
both phenotypic and molecular methods in different E. coli
strains [132].
The ﬁrst KPC-producing isolate was identiﬁed from a
patient transferred directly from New York in February
2005 [21]. After that, several reports were published related
to KPC importation from the USA, Israel, and Greece
[30,133,134]. In France, KPC-producing K. pneumoniae iso-
lates remain rare, and, to date, have always been linked to
patients transferred from a country where KPC enzymes are
endemic (Israel, Greece, the USA and, recently, Italy) [135].
In some cases, hospital outbreaks have been described [135],
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but nosocomial regional interhospital dissemination mediated
by a contaminated duodenoscope has also been reported
[136,137]. Most KPC producers have been nosocomial
K. pneumoniae ST258 isolates and, to a lesser extent, E. coli
and other enterobacterial species [135,138]. Recently, the
E. coli ST131 clone, the main clone responsible for CTX-M-
15 diffusion in the community, was shown to harbour the
blaKPC-2 gene along with the narrow-spectrum TEM-1 and
OXA-9 b-lactamases, and the CTX-M-9 ESBL [139]. It was
isolated from a urinary tract infection from a 64-year-old
bedridden woman hospitalized in the gerontology ward of
Lille University Hospital (France) [139]. Other class A carba-
penemases have rarely been described in France. One IMI-1-
producing E. cloacae [140] isolate and three IMI-2-producing
Enterobacter asburiae isolates have recently been described
(P. Nordmann, unpublished data).
Finally, the ﬁrst OXA-48-producing isolate was a K. pneu-
moniae isolate identiﬁed in Paris in 2009 from the sputum of a
patient transferred from Tunisia [141]. Subsequently, other
OXA-48-producing K. pneumoniae isolates were found in
patients transferred from countries around the Mediterranean
sea (Turkey, Egypt, Algeria, Libya, Tunisia and, mostly, Mor-
occo) [24,59,117,142–144]. They were associated with several
outbreaks [145]. OXA-48 is mainly found in unrelated K. pneu-
moniae clones detected across Europe and in E. coli isolates
associated with clones previously linked with ESBLs in patients
without a history of prior hospitalization [25]. However, very
recently, an identical or clonally related K. pneumoniae OXA-
48 producer was identiﬁed in France, The Netherlands, and
Morocco [53]. A point mutant derivative, OXA-181, has been
isolated from patients transferred from India [146].
Since August 2001, France has implemented a mandatory
national nosocomial infection notiﬁcation system. The base-
line reporting requires the use of strict criteria; one of them
is about rare or noticeable microorganisms, depending on
virulence and/or antimicrobial susceptibility (Coignard et al.,
SHEA 15th Annual Scientiﬁc Meeting, 2005, Abstract B306).
Notiﬁcation of CPE to the French Institute of Health (InVS)
is recommended. From 2004 to 2009, only isolated CPE
cases were notiﬁed to the health authorities. Since 2009, the
number of notiﬁcations per year has increased (six in 2009;
28 in 2010, and 62 in the ﬁrst 9 months of 2011). A total of
104 cases have been notiﬁed (http://www.invs.sante.fr/con-
tent/download/21883/128402/version/3/ﬁle/Bilan+EPC_270911.
pdf). These CPE isolates were mostly K. pneumoniae (59%),
E. coli (22%), E. cloacae (12%), and various other enterobacte-
rial species. The most prevalent carbapenemases were OXA-
48 (51%), KPC (25%), VIM (9%), NDM (13%), IMI-1 (1%),
and IMI-2 (1%). A link to foreign countries (patients trans-
ferred from foreign hospitals, previously hospitalized in a
foreign country, and having undertaken recent travel to a
foreign country) has been established for 76 of the cases
(73%). These countries are mostly Greece, Morocco, and
India. For 28 episodes, no link to a foreign country could be
established, and among these, 21 involved OXA-48-like pro-
ducers. These latter isolates were recovered in several parts
of France, suggesting intra-country dissemination of these
isolates, probably linked to the difﬁculty in detection of
OXA-48-producing CPE isolates or to community dissemina-
tion from North Africa. These 104 episodes involved a total
of 249 patients; 68 of them (29%) were infected and 170
(71%) were colonized. Most of the notiﬁcations related to
single isolation of CPE, but epidemics involving up to 44
patients have also been described.
As the number of CPE cases in France remains low, in
December 2010 the French health authorities implemented
(Circulaire DGS/DGOS 06/12/2010 Controˆle des cas import-
e´s d’EPC; http://www.circulaires.gouv.fr/pdf/2010/12/
cir_32240.pdf) guidelines in order to build a ‘line of defence’
based on systematic screening for MDR bacteria for every
patient transferred from foreign hospitals, or with a previous
hospitalization in a foreign country, or who had undertaken
a recent trip to a country with high prevalence, and to main-
tain contact isolation and strict hygiene measures for these
patients, until screening results are available. Compliance
with these rules would allow the containment of many epi-
sodes to a single case.
In Switzerland, the ﬁrst CPE isolate was an SME-2-produc-
ing Serratia marcescens strain isolated in May 2006 at the Uni-
versity Hospital of Lausanne, Switzerland [147]. SME-2 is a
clavulanic acid-inhibited class A carbapenemase, and its gene,
blaSME-2, is chromosomally encoded. Subsequently, a few
cases of imported KPC producers have been described. A
K. pneumoniae isolate producing KPC-2 was probably
imported as a result of the transfer of a patient from Sicily,
Italy, to the Neuchaˆtel public hospital in Switzerland in mid-
2000 [148]. Four epidemiologically unrelated cases of KPC-
producing K. pneumoniae were identiﬁed in Switzerland
between May 2009 and November 2010; three cases were
transferred from Italy (two KPC-3; one KPC-2) and one
from Greece (KPC-2) [149]. During analysis of the mecha-
nisms responsible for decreased susceptibility or resistance
to carbapenems in several enterobacterial isolates recovered
in 2009–2010 in Geneva University Hospitals, Switzerland,
three patients were found to be positive for NDM-1-produc-
ing enterobacterial isolates (one with E. coli and K. pneumo-
niae, one with K. pneumoniae only, and one with Proteus
mirabilis) [150]. This study constitutes the ﬁrst identiﬁcation
of NDM-1 producers in Switzerland. Interestingly, patients
from whom these NDM-1-producing isolates were recov-
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ered had a link to the Indian subcontinent or the Balkans.
Finally, a few cases of OXA-48-producing K. pneumoniae
identiﬁed in Geneva University Hospitals were probably
transferred from North African countries (P. Nordmann and
J. Schrenzel, unpublished data).
Belgium, Luxembourg, and The
Netherlands
Although there is currently no mandatory reporting of carba-
penem-resistant Gram-negative bacilli in Belgium, the
National Reference Centre for MDR Enterobacteriaceae has
been recording the proportion of CPE isolates detected. In
2007, only two isolates (8%) of those referred to this centre
that were not susceptible to carbapanems were CPE, VIM-2
being the single carbapenemase found at that time. In 2010
and 2011, this situation rapidly changed, with 18 isolates of
94 (19.1%) referred in 2010 and 60 of 197 (30.5%) in
referred 2011 being conﬁrmed as CPE by the National Ref-
erence Centre. A variety of enzymes were found in these
isolates, mainly OXA-48, VIM, and KPC. In 2010, sporadic
NDM-producing isolates were detected for the ﬁrst time in
Belgium. The most frequent Enterobacteriaceae species by far
was K. pneumoniae (69%), followed by Enterobacter cloacae
(15%) and E. coli (6%). These isolates were found all over the
country [151]. Although initial sporadic occurrence of CPE
in Belgium was reported in patients returning from travel
abroad [41,104], the majority of patients (70%) carrying CPE
did not have a history of travel abroad or cross-border
transfer, demonstrating potential secondary or autochtho-
nous acquisition.
Today, the most prevalent carbapenemase in Enterobacteria-
ceae in Belgium by far is OXA-48 (Fig. 3)[151]. Although most
OXA-48-producing isolates have been found to represent
asymptomatic cases in the urinary tract in elderly patients, a
few cases of bacteraemia and of systemic infections have been
recorded among patients in ICUs, and independent local out-
breaks were reported in at least three hospitals in Belgium in
2010 and in 2011 [151–153]. In this country, carbapenemases
were ﬁrst detected in Acinetobacter (OXA-58), and later, in
2008, in K. pneumoniae (VIM-1), and were implicated in differ-
ent nosocomial outbreaks, as in France and The Netherlands
[41,151–153]. A recent study highlighted this situation, with
OXA-48 enterobacterial isolates also producing ESBLs (CTX-
M-9, CTX-M-15, or SHV variants) [154]. Other carbapene-
mases from Belgium include KPC-2, which emerged within
ST258 K. pneumoniae in 2009 in a patient transferred from
Greece [104], and NDM-1, which emerged in 2010 in non-
clonally related Enterobacteriaceae from three patients who
had been hospitalized in Pakistan, Montenegro, and Serbia/Ko-
sovo [152]. NDM-1 was detected in all of the isolates, in addi-
tion to several ESBLs (CTX-M-15 and SHV-12), acquired
AmpCs (CMY-16 and CMY-58), 16S rRNA methylases (ArmA
and RmtB), and Qnr genes (qnrA6, qnrB1, and qnrB2). Screen-
ing for intestinal carriage of carbapenemases and strict infec-
tion control measures prevented secondary cases [152].
The situation in The Netherlands is probably similar to that
in Belgium, with OXA-48 now being one of the most preva-
lent carbapenemases [53,155]. This enzyme was associated
with an important outbreak at one hospital in Rotterdam, and
was linked to a widespread ST395 K. pneumoniae clone also
producing CTX-M-15 found in France that may have its origin
in North Africa [156]. This clone has been found in a hospital
in Morocco and also in the environmental setting [156].
Other carbapenemases found in The Netherlands are KPC-2
and NDM-1, both of them in K. pneumoniae isolates from
patients with a history of travel to Greece and India, respec-
tively [157]. In Luxembourg, as in Belgium and The Nether-
lands, sporadic cases of VIM-type carbapenemases (VIM-1 and
VIM-27) have also been found in patients repatriated from
hospitals in Greece [158] (Y. Glpczynski, unpublished data).
Germany and Austria
In the 2010 Annual report of the European Antimicrobial
Resistance Surveillance Network (http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/database/Pages/database.
aspx), one case was reported from Germany of invasive
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FIG. 3. Evolution of the carbapenemase-producing Enterobacteriaceae
(CPE) isolates in Belgium (92 isolates referred to the National Refer-
ence Centre, Belgium, January 2007–December 2011) (data have
been updated from reference 150).
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infection caused by carbapenem-resistant Enterobacteriaceae.
In 2009, the German National Reference Laboratory for Mul-
tidrug-Resistant Gram-negative Bacteria was inaugurated
(Nationales Referenzzentrum fu¨r gramnegative Krankenhaus-
erreger, Institute for Medical Microbiology, Ruhr-University
Bochum; heads, S. G. Gatermann and M. Kaase). Since
August 2009, microbiological laboratories in Germany have
been encouraged to send Gram-negative bacilli with sus-
pected carbapenem resistance to the national reference cen-
tre, which offers molecular characterization of resistance
mechanisms of the submitted isolates. No systematic data
are collected, and the data obtained do not allow prevalence
rates to be determined for Germany; likewise, no denomina-
tor data and no clinical data are obtained. In 2010, the
national reference centre received 808 Gram-negative bacilli
with elevated carbapenem MICs, and 621 of these isolates
were analysed for the presence of a carbapenemase (405 En-
terobacteriaceae; 127 P. aeruginosa; 86 A. baumannii). Two
hundred and eighty-nine of them were found to harbour a
carbapenemase, whereas reduced carbapenem susceptibility
in the remaining isolates was conferred by porin loss com-
bined with either ESBL or AmpC enzymes (http://
www.rki.de/cln_109/nn_2030884/DE/Content/Infekt/EpidBull/
Archiv/2011/32/Tabelle.html?__nnn=true). Among CPE iso-
lates, the majority were K. pneumoniae (n = 111), followed
by E. coli (18), Enterobacter cloacae (17), K. oxytoca (6), and
C. freundii (5). The predominant carbapenemases in the dif-
ferent species were as follows: in K. pneumoniae, OXA-48
(43%), KPC-2 (23%), and KPC-3 (23%); in E. coli, OXA-48
(44%) and VIM-1 (28%); in Enterobacter cloacae, VIM-1 (71%);
and in K. oxytoca, VIM-1 (83%). NDM-1 was found in only
two K. pneumoniae isolates and in two E. coli isolates.
Despite the dominance of OXA-48, for outbreaks in Ger-
many only KPC-producing K. pneumoniae isolates have been
reported, one of them also co-producing VIM-1 [159,160].
In Austria, few reports have recognized the presence of
CPE [161–163]. One of them records emergence in the year
2005, with a remarkable increase in the number of involved
patients in 2010. Carbapenem-resistant Enterobacteriaceae
comprise K. pneumoniae, K. oxytoca and E. coli isolates with
NDM, VIM, IMP, and KPC enzymes, showing the complexity of
CPE. NDM-1 producers have been related to a Balkan origin.
Poland, the Czech Republic, Hungary, and
Romania
According to the surveillance data collected by the National
Reference Centre for Susceptibility Testing (NCRST) in
Warsaw, most of the CPE isolates detected in Poland so far
have been KPC producers. The ﬁrst KPC-positive K. pneumo-
niae isolates reported were recovered in May 2008 in War-
saw. The isolates belonged to the ST258 clone, and
produced KPC-2 together with the ESBL SHV-12. As the
patient had not travelled for a long period before that time
but had a history of previous hospitalization in Warsaw, it is
likely that KPC producers had been present before this ﬁrst
report [164].
Soon thereafter, the next organisms suspected of being
KPC producers were sent to the NRCST by several hospi-
tals, and by the end of 2008, 33 unique KPC-positive isolates
from 32 patients in total had been conﬁrmed. These were
30 K. pneumoniae and three K. oxytoca isolates, and were
recovered in ﬁve Warsaw hospitals, three of which experi-
enced outbreaks. The situation developed further in 2009,
with 86 non-duplicate isolates from 82 patients, these being
84 K. pneumoniae and two E. coli isolates (the E. coli isolates
were co-isolated with K. pneumoniae from a single patient).
Most of the patients were hospitalized in 12 centres in the
Warsaw area; moreover, three outpatients and one nursing
home resident were diagnosed there as well. KPC producers
were also identiﬁed in six other cities, in three cases follow-
ing patient transfer from Warsaw, and in one case following
patient transfer from New York. The molecular analysis of
all isolates collected in 2008–2009 [165] revealed that 97.4%
of the K. pneumoniae isolates were ST258, and only sporadic
isolates belonged to ST11 or ST23. The two E. coli strains,
being likely recipients of blaKPC-carrying plasmids from
K. pneumoniae, were ST93 and ST224. Almost all of the iso-
lates produced KPC-2; the only two exceptions, including
the isolate from New York, expressed KPC-3. In all but one
case, the blaKPC genes were located in the Tn4401a transpo-
son [166], carried by plasmids ranging from c. 48 to 250 kb.
The most prevalent plasmids were conjugative IncFIIK
(c. 110–160 kb), identical or similar to the pKpQIL plasmid
characterized in Israel [167]. The other prevalent plasmid
was the non-typeable pETKp50 of c. 50 kb [168], with low
transfer potential. Signiﬁcant groups of the isolates produced
the ESBLs SHV-12 and/or CTX-M-3. In general, the analysis
revealed a major role of K. pneumoniae ST258 and pKpQIL-
like molecules in the early spread of KPC-positive organisms.
The diversity of the strains was attributed to several possible
introductions of these into the country, their evolution dur-
ing clonal dissemination, and transfer of plasmids [165].
In 2010, the NRCST conﬁrmed 153 unique KPC-produc-
ing isolates, mostly K. pneumoniae (one E. coli). This increase
was mostly attributable to the continuous spread in central
Poland (region Mazowsze, including Warsaw), from where
126 isolates from 32 healthcare institutions were collected
(106 isolates from 26 sites in the Warsaw area alone). Of
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note was a local outbreak in another region (S´wie˛tokrzyskie)
involving ﬁve hospitals in four locales, from which 19 unique
isolates were conﬁrmed in 2010. It is possible that wider
implementation of the national guidelines for infection con-
trol (http://www.korld.edu.pl) helped to reduce the total
number of cases conﬁrmed to 104 in 2011. The Warsaw
area continued to be the most affected; however, even more
concern has been caused recently by a new outbreak in the
region Podlasie (northeastern Poland), which started in Feb-
ruary (possibly with a patient from the USA). By the end of
2011, the NRCST had conﬁrmed 29 unique isolates from ten
hospitals, including six centres in the main city Białystok, and,
despite many efforts of the infection control specialists, the
increase has been continuing to date (M. Gniadkowski, A.
Baraniak, D. _Zabicka, E. Tryniszewska, W. Hryniewicz,
unpublished data).
Considering all of the data, it is clear that KPC spread has
become the major issue in Poland. The total number of
patients conﬁrmed from 2008 to 2011 was 371, and it has
been certainly underestimated. At least 58 hospitals in 34
locales have faced the problem, and even though the major-
ity of these have apparently managed to control the situa-
tion, the notable number of institutions constitutes a
reservoir for further spread. Of the three regional outbreaks
observed, those with epicentres in Warsaw and Białystok
are far from being successfully controlled.
There has been much less information concerning MBL-
producing Enterobacteriaceae in Poland. The ﬁrst such isolate
reported, K. pneumoniae with VIM-4, was identiﬁed in 2006
in a hospital in Bydgoszcz [169] (I. Kern-Zdanowicz, M.
Gniadkowski, unpublished data). In 2006–2008, the NRSCT
conﬁrmed eight MBL-positive isolates; however, in 2009,
2010, and 2011, these numbers were 22, 23, and 31, respec-
tively (all of the isolates were collected from 39 hospitals in
24 cities). This increase may have been caused by the grow-
ing awareness of hospital laboratories regarding carbapenem
resistance in enterobacteria and/or the actual dissemination
of these organisms. Interestingly, the predominant species
have been Enterobacter cloacae (50.0%), followed by S. marces-
cens (17.9%), K. oxytoca (16.7%), and K. pneumoniae (11.9%).
Most of the isolates analysed so far have produced VIM-type
MBLs (93.8%); three isolates had IMP types, and recently the
ﬁrst E. coli isolate with an NDM-like enzyme was recovered
in Warsaw from a patient who had been moved from a hos-
pital in the Congo (M. Gniadkowski, J. Fiett, D. _Zabicka, K.
Filczak, W. Hryniewicz, unpublished data).
In the Czech Republic, the situation regarding CPE is
much better than in Poland; however, in 2011, the National
Reference Laboratory for Antibiotics in Prague observed sig-
niﬁcant increases in the numbers of both MBL-positive and
KPC-positive cases (J. Hraba´k, P. Urba´sˇkova´, H. Zˇemlicˇkova´,
personal communication). Regarding MBL producers, from
2009 to 2010, ﬁve VIM-1-producing isolates (four S. marces-
cens and one Enterobacter cloacae) were recovered from spo-
radic infections in Opava, Havı´rˇov (the area of Ostrava), and
from a large hospital in Prague (three cases). Interestingly, in
2011, this Prague hospital recorded eight new cases, but
most of these involved K. pneumoniae isolates with another
blaVIM-1-carrying integron, indicating the new emergence of
VIM-1 producers in that centre. Additionally, two other hos-
pitals reported MBL-positive K. pneumoniae, including one
VIM-1 producer imported by a patient from Greece. Also
from Greece, the ﬁrst Czech patient infected with a K. pneu-
moniae ST258 KPC-2 producer was admitted to the Havı´rˇov
hospital in July 2009 [170]. In 2011, 11 unique KPC-produc-
ing K. pneumoniae isolates were identiﬁed in ﬁve hospitals in
Prague, including six isolates from an outbreak in one hospi-
tal with a patient returning from Italy. Of the remaining ﬁve
cases, three were linked to the previous hospitalization in
Greece.
In Hungary, a local outbreak of KPC-2-producing and
SHV-12-producing K. pneumoniae ST258 was reported in
2008–2009 in the north-eastern part of the country; this
started with a patient who had been hospitalized in Greece
[171]. In 2009, single isolates of K. pneumoniae ST11 and
K. oxytoca carrying the same integron with the blaVIM-4 gene
cassette were identiﬁed in two different hospitals [145].
KPC-producing Enterobacteriaceae have been recently
detected in Romania (Y. Carmeli, unpublished data), as well
as cases of NDM producers abroad associated with travellers
to this country (Ø. Samuelsen, unpublished data).
UK and the Republic of Ireland
There is no mandatory reporting of carbapenem-resistant
Gram-negative bacilli in the UK. However, the Antibiotic
Resistance Monitoring and Reference Laboratory (ARMRL)
of the Health Protection Agency (HPA) encourages referral
(see http://www.hpa.org.uk/ProductsServices/InfectiousDis-
eases/LaboratoriesAndReferenceFacilities/AntibioticResistance
MonitoringAndReferenceLaboratory/), and seeks carbapene-
mases in these: (i) if they are conﬁrmed to be resistant to at
least one carbapenem; and (ii) if that resistance cannot be
attributed to a non-carbapenemase mechanism by interpreta-
tive reading of the complete antibiogram. The HPA, together
with the UK Government’s ARHAI Committee, has issued
‘Advice on Carbapenemase Producers: recognition, infection
control and treatment’ (http://www.hpa.org.uk/web/HPAweb
File/HPAweb_C/1294740725984).
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The ﬁrst conﬁrmed isolate in the UK with an acquired
carbapenemase was an Acinetobacter isolate with IMP-1 in
2000 [172], but this genus has not proved to be a frequent
host of metalloenzymes in the UK. The ﬁrst conﬁrmed CPE
isolates were referred to the ARMRL in 2003. These were
an isolate of Enterobacter with KPC-4, and two isolates of
Klebsiella with IMP-type and VIM-type enzymes. Fewer than
ﬁve CPE isolates were conﬁrmed in the UK in each of the
next 4 years (2004–2007). They were mostly isolated from
patients with a history of travel and hospitalization, often fol-
lowing road trafﬁc accidents, in endemic areas, e.g. KPC pro-
ducers from Greece or Israel [173], VIM-positive klebsiellae
from Greece, and an OXA-48 producer from Turkey.
From 2008, the numbers of conﬁrmed CPE increased dra-
matically: 23 in 2008, 73 in 2009, 333 in 2010, and 561 in
2011 (at the time of writing, the 2011 database is not yet
closed). Most producers were Klebsiella (80%), mainly
K. pneumoniae, followed by E. coli (10%) and Enterobacter
(8%), with the remaining 2% comprising occasional isolates of
Citrobacter, Morganella, Providencia, Raoultella and Serratia. The
enzymes produced included KPC (62%), NDM (14%), VIM
(12%), OXA-48-like (9%) and IMP (2%) types. A single isolate
of Klebsiella produced both KPC and VIM enzymes. Three
isolates of Enterobacter with IMI/NMC-A enzymes were
detected in 2010–2011, each from a different hospital.
Although Enterobacteriaceae with KPC enzymes were
most commonly referred, the numbers are skewed by an
ongoing problem in north-western England, which involves
the transmission of pKpQIL-like plasmids [167], encoding
KPC-2 among different bacterial strains, principally of
K. pneumoniae, but with spread also to E. coli and Enterob-
acter (N. Woodford and D. M. Livermore, unpublished
data). Referrals from this region accounted for c. 75% of
the UK’s total number of KPC-positive isolates, with many
of these isolates being obtained from faecal screens rather
than infections. Similarly, a small number of hospitals in one
region shared an ongoing outbreak of VIM-positive klebsiel-
lae, which also extended to the community, and these
accounted for the majority of the UK total with this carba-
penemase. In 2008, there was an outbreak, centred on a
London renal unit, caused by K. pneumoniae with OXA-48;
there was a dominant outbreak strain, but with horizontal
transfer of an OXA-48-encoding plasmid to other strains
(Thomas et al., 49th ICAAC, 2009, Abstract C2-648).
Although less numerous than KPC producers, bacteria
with NDM enzymes [8,23] have the widest distribution in
the UK; 55 laboratories referred at least one producer after
the enzyme was ﬁrst detected in 2008, as compared with 42
referring isolates with KPC enzymes and 22 with VIM types
(Fig. 4).
The UK has recorded more NDM cases than any other
European country [116], and, to the end of 2011, genes
encoding NDM enzymes had been detected in 138 isolates
of Enterobacteriaceae and also in 11 A. baumannii isolates, col-
lectively from 115 patients. Multiple species with NDM
enzymes were isolated from several patients, which is consis-
tent with either in vivo transfer of a resistance plasmid or ini-
tial colonization/infection by more than one species.
There is no coordinated epidemiological follow-up for
these cases, and the HPA has a travel history, albeit limited,
for only 53/115 (46%) patients with NDM-positive isolates,
32 (60%) of whom were known to have travelled to or had
healthcare contact in India (n = 25) or Pakistan (n = 7).
The antibiograms of carbapenemase producers are highly
variable, and range from extreme multiresistance to resistance
only to b-lactams. Many K. pneumoniae isolates from the large
KPC cluster in north-western England remain susceptible to
aminoglycosides and ciproﬂoxacin, and, as noted earlier, pro-
ducers of OXA-48-like enzymes may remain susceptible to
oxyimino-cephalosporins unless they have other co-resident
mechanisms, such as ESBLs or AmpC enzymes. In 2011 analy-
ses, only colistin was active against >90% of all UK carbape-
nemase producers. Tigecycline was active against some
producers, notably vs. E. coli, but a breakthrough bacteraemia
caused by an NDM-positive E. coli isolate that became resis-
tant to tigecycline during on-label use of the drug has been
described [174]. In short, therapy of patients infected by carb-
apenemase-producing bacteria must be guided by the resis-
tance proﬁle of the causative isolate, which may remain
susceptible to less commonly tested agents [175].
The ﬁrst published report of CPE in Ireland was of a
KPC enzyme in a K. pneumoniae isolate recovered in 2009
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FIG. 4. Numbers of UK laboratories referring at least one carbape-
nemase-producing Enterobacteriaceae (CPE) isolate to the Antibiotic
Resistance Monitoring and Reference Laboratory (ARMRL) (Health
Protection Agency). Additionally, in 2010 and 2011, two and one lab-
oratories, respectively, referred IMI-producing CPE isolates, respec-
tively. In 2011, one laboratory referred at least one CPE isolate
producing both KPC and VIM enzymes.
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from a sputum sample collected 48 h after hospital admis-
sion in a patient with exacerbation of chronic obstructive
pulmonary disease. No association with travel abroad was
demonstrated in this patient [176]. The second one
reported the emergence of a VIM-1-producing K. pneumo-
niae isolate in 2010 in a patient transferred from Greece
[177]. Subsequently, there has been regional spread of
KPC producers (Condon et al., 21st ECCMID, 2011,
Abstract P73), with isolates being detected in four hospi-
tals (D. Morris, personal communication). It is of note that
KPC-2 has also been detected in an E. coli isolate belong-
ing to the uropathogenic ST131 clone [178]. K. pneumoniae
isolates with OXA-48-like enzymes have also been
obtained from at least four Irish hospitals (D. Morris, per-
sonal communication). The only ‘OXA-48’ outbreak
reported to date was caused by a strain that belonged to
ST221 [179] (B. Crowley, personal communication). OXA-
48 has also been detected in a single E. coli isolate (D.
Morris, personal communication). Although not formally a
reference laboratory for Ireland, the ARMRL has con-
ﬁrmed 30 CPE isolates from Irish laboratories since 2009.
Consistent with the above reports, most referred isolates
were KPC producers, but isolates of K. pneumoniae with
OXA-48 and of Enterobacter cloacae with a VIM-type
enzyme were also referred. Ireland’s ﬁrst NDM-1 pro-
ducer—a K. pneumoniae strain—was recently isolated from
a urine specimen of a child who had moved to Ireland
from India (R. Cunney, personal communication).
Nordic and Baltic Countries
During the early 2000s, there were no reports on CPE from
any of the Nordic countries. Approaching the end of the
decade, and particularly in the last 3 years, the number of
cases has increased rapidly, but still remains very low. In
most of the countries, laboratories are encouraged to send
suspected CPE isolates to reference laboratories, but the
number of cases is too low for it to be meaningful to con-
sider denominator data. In all of the Nordic countries, there
were, in total, 41 cases of CPE in 2011. There have been
few cases of invasive infections caused by CPE, although one
case of invasive VIM-producing K. pneumoniae, one case of
KPC-producing K. pneumoniae and one case of invasive
NDM-1-producing E. coli have been observed over a 5-year
period [42,58,180].
There have been no reports so far of CPE from the Baltic
countries and from Iceland, whereas all of the other Nordic
countries have experienced cases. In general, the awareness
of CPE is high in Nordic hospitals, and active faecal screening
is conducted in many locations on patients with a history of
recent travel or hospitalization abroad.
The most prevalent class of carbapenemases observed in
the Nordic countries has been KPC, and almost exclusively
in K. pneumoniae. In total, 14 cases have been identiﬁed in
Norway, 14 cases in Sweden, three cases in Denmark, and
ﬁve cases in Finland. KPC-2 has most commonly been identi-
ﬁed, but cases of KPC-3 have also been demonstrated. The
cases have mostly been associated with strain imports from
Greece, Israel, the USA, or Italy; however, subsequent cases
of nosocomial transfer and a small long-term outbreak have
been observed [42] (Ø. Samuelsen, unpublished data).
Mostly, KPC enzymes have been found in K. pneumoniae of
ST258 or in STs belonging to the same clonal complex
[42,181–184]. The plasmid epidemiology has been less well
characterized, and at present it has not been established
which plasmid types are mainly associated with the spread of
KPC. Finally, of the minor class A carbapenemases, GES-14
and IMI-1/2 have been detected in Finland in K. pneumoniae
(GES-14) and Enterobacter cloacae (IMI-1/-2).
MBLs are the second most common group of enzymes
produced by CPEs, and, historically, VIM has been the most
common variant. Since the ﬁrst case of NDM-1 in Sweden in
2008 [8], this MBL has become as common as VIM, especially
in Sweden (C. G. Giske, upublished data). The cases have
usually been associated with recent travel to India [8,145] or
the Balkan region [182], or have been connected to Middle
Eastern countries or even Thailand (C. G. Giske, unpublished
data) and Romania (Ø. Samuelsen, unpublished data). Many
of the VIM-producing K. pneumoniae isolates belong to inter-
national clonal complexes such as ST147, and association
with IncN-type plasmids is common [58]. The NDM-produc-
ing K. pneumoniae isolates have been associated with ST14,
ST11, and ST525 [8,177] (Ø. Samuelsen unpublished data),
whereas the plasmid epidemiology has been less well studied,
with the exception of the identiﬁcation of NDM-1 on an
IncA/C plasmid in an isolate from Denmark [181]. The num-
ber of cases identiﬁed in the Nordic countries so far are as
follows: Norway, seven cases (four VIM and three NDM-1);
Sweden, 16 cases (six VIM and ten NDM-1); Denmark, six
cases (three VIM and three NDM-1); and Finland, seven
cases (four VIM and three NDM-1).
OXA-48-like enzymes are emerging as an important third
group of carbapenemases. In the Nordic countries, most of
the cases with OXA-48 or OXA-48-like enzymes have been
associated with travel or hospitalization in North Africa and
Middle Eastern countries, similar to what has been reported
from other European countries. No published data are avail-
able on STs and plasmid characterization so far. OXA-48-like
enzymes have been detected so far in Finland (n = 10),
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Denmark (n = 7), Sweden (n = 4), and Norway (n = 1),
including several cases in E. coli (C. G. Giske, Ø. Samuelsen,
A. M. Hammerum, J. Jalava, unpublished data).
Conclusions
Carbapenemases in Enterobacteriaceae are mostly plasmid-
encoded, which largely explains their common association
with other resistance markers and their multidrug resistance
patterns. The prevalence of the CPE is variable across Eur-
ope; a high prevalence can be found in Greece, Italy, Turkey,
and Israel, whereas a low prevalence is still reported in Nor-
dic countries, Switzerland, Germany, and the Czech Republic.
The type of CPE depends on the country, and might be asso-
ciated with historical/cultural relationships and exchange of
populations with other countries of high prevalence. Cross-
border transfer of patients, travel, medical tourism and refu-
gees might also play an important role. This is particularly
true for the spread of OXA-48 in France and in Belgium
from North Africa, and in Germany, probably from Turkey,
or the identiﬁcation in UK of NDM-1 producers of Indian
origin. The clearly increasing frequency of CPE in recent last
years could be related to the increasing prevalence of OXA-
48 producers in many European countries and the exporta-
tion of KPC producers from Greece and Italy to other Euro-
pean countries. In many cases, the spread of CPE results
from hospitalization abroad. More important are the cases
without importation links, which may represent community-
acquired and/or autochthonous cases. In addition, although a
polyclonal situation has been observed for CPE in many
countries, some widespread clones have also been detected
across Europe (KPC-2-producing K. pneumoniae ST258 or
OXA-48-producing K. pneumoniae ST395).
The future trend of this CPE epidemic will be one of
increase, as the reservoirs of carbapenemase producers are
growing worldwide. Although dissemination of CPE mainly
occurs among hospitalized patients (K. pneumoniae), commu-
nity acquisition is increasing (especially for OXA-48 produc-
ers). A well-concerted effort all over Europe is clearly
needed to prevent the further spread of CPE, and hence to
avoid an uncontrollable situation as can now be observed
worldwide for CTX-M ESBL producers.
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